Jeil's TS-1 may shake whole cancer drug markets.

Jeil Pharmaceutical Co. will introduce an attractive ant-cancer drug named TS-1 formulated with 3 components such as Tegaflu, Kimeracil and Oteracil under the technical licence with Japanese Taiho who originally developed it in 1997.

Compared to overall 25-30% of anti-cancer effectiveness with existing drugs, the phase II clinical studies of TS-1 reveals a significant effectiveness; the sto...